Clinical Trial Update: ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability [Phase 1]

View source ↗

Summary

Phase 1 trial of Pemvidutide (ALT-801) in healthy overweight and obese volunteers to assess safety and tolerability has been completed. The study addresses obes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis
• Obesity

Drugs mentioned

• Pemvidutide (ALT-801) (pemvidutide)

Snippet

Sponsor: Altimmune, Inc. | Conditions: Obesity, Nonalcoholic Steatohepatitis | Phase 1 | Status: COMPLETED